Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial
Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Nauman Butt, Aart Beeker(Spaarne Ziekenhuis), Eloise Beggiato, Valentín García‐Gutiérrez(Universidad de Alcalá), Anna Angona(Hospital Del Mar), Amama Sadiq(Karyopharm Therapeutics (United States)), Bhavana Bhatnagar(The Ohio State University), Fiorenza Barraco(Hôpital Lyon Sud), Françoise Boyer‐Perrard(Centre Hospitalier Universitaire d'Angers), Жанет Грудева-Попова(Medical University Plovdiv), Emanuele Ammatuna(University Medical Center Groningen), Laura Urian(Iuliu Hațieganu University of Medicine and Pharmacy), Yi Chai(Karyopharm Therapeutics (United States)), Aitor Abuín Blanco, Tomer Mark(Karyopharm Therapeutics (United States)), Pankit Vachhani(University of Alabama at Birmingham), Srinivas Tantravahi(Huntsman Cancer Institute), Gabriela Borsaru, Christopher Benton, Reshma Rangwala(Karyopharm Therapeutics (United States)), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), for the SENTRY Trial Investigators, Raajit Rampal(Memorial Sloan Kettering Cancer Center), Sebastian Grosicki(Medical University of Silesia), Junshik Hong(Seoul National University Hospital), Hsin-An Hou(National Taiwan University Hospital), Celeste Bremer, Andrea Patriarca(Piedmont University), Francesco Passamonti(University of Milan), Haifa Kathrin Al-Ali(University Hospital in Halle), Michal Kwiatek(Centralne Laboratorium Kryminalistyczne Policji), Haris Ali(City of Hope), John Mascarenhas(Icahn School of Medicine at Mount Sinai), Nikolai Podoltsev(Yale University), Joseph Brandwein, Seo-Yeon Ahn, Sabrina Barriere, Soo-Mee Bang, Rosa Ayala, Massimiliano Bonifacio, Alberto Alvarez-Larran, Aleksandra Butrym, Haifa Kathrin Al-Ali(University Hospital in Halle), Petra Belohlavkova, Michael Loschi(Centre Hospitalier Universitaire de Nice), Massimo Breccia, Pietro Taverna
Cited by 1
Related Papers
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|582
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial
|The Lancet Oncology|2015|380